Despite Japan being free of rabies for 50 years now, the disease remains endemic in most countries. This is because these countries often do not have sufficient funds or the infrastructure required to employ the approved gold standard for the definitive diagnosis of the disease. The disease is extremely serious, infecting the brain and nerves and causing inflammation. What is more, once symptoms have appeared, the prognosis is nearly always death. More research surrounding the disease is required in order to successfully diagnose and ultimately combat it. Research led by Chief Investigator Professor Akira Nishizono at Oita Medical University in Japan, is seeking to ultimately combat the ongoing issue of endemic rabies using a new method – RAPINA. The novel approach has been specifically developed to quickly, easily and efficiently determine viral neutralising antibody (VNA) levels. This is crucial because rapidly and easily determining the VNA level against the rabies virus is key to evaluating the protective immunity of humans and dogs, and also for assisting in the strategy of eradication programmes. RAPINA is an improved rapid neutralising antibody detection system that the team has developed with a view to providing an alternative to existing VNA determination assays. The determination of the VNA response following immunisation against rabies is an indicator of how effective the vaccine has been.